Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis
Primary Purpose
Onychomycosis
Status
Unknown status
Phase
Phase 2
Locations
Brazil
Study Type
Interventional
Intervention
Er:YAG laser + amorolfine lacquer
Amorolfine lacquer
Sponsored by
About this trial
This is an interventional treatment trial for Onychomycosis focused on measuring Erbium-doped yttrium aluminium garnet laser, Er:YAG, Amorolfine lacquer, Dermatophytes, Subungual distal lateral onychomycosis, Drug delivery
Eligibility Criteria
Inclusion Criteria:
- 19-60 year-old
- preserved cognitive status
- direct mycological examination or culture showing infection of hands or feet nails by dermatophyte molds
Exclusion Criteria:
- diabetes type 1 or 2; peripheral vascular disease
- having undergone any treatment in the last 6 months
- peripheral nerve disorders (e.g. peripheral neuropathy, Hansen's disease, etc)
- willing to paint nail during the study
- high blood pressure
- use of any immunosuppressive drugs; congenital or acquired immunodeficiency
Sites / Locations
- University Hospital of BrasiliaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Er:YAG + amorolfine lacquer
Amorolfine lacquer
Arm Description
30 ungual units affected by onychomycosis due to dermatophytes
30 ungual units affected by onychomycosis due to dermatophytes
Outcomes
Primary Outcome Measures
Extent of nail plate damage
At the beginning and after 6 months of treatment both the group, A and B, will have the length from nail cuticle to the closest point of damage to the nail plate measured by a millimeter scale. It will later be accessed to determine the clearance rate of the nail plate achieved with each treatment
Secondary Outcome Measures
Mycological cure
After 6 months of treatment both the group, A and B, will be accessed by direct mycological examination and culture to evaluate mycological cure
Clinical cure
After 6 months of treatment both the group, A and B, will be accessed by dermatological examination to evaluate clinical cure
Full Information
NCT ID
NCT01528813
First Posted
February 5, 2012
Last Updated
August 5, 2013
Sponsor
Brasilia University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01528813
Brief Title
Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis
Official Title
AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Unknown status
Study Start Date
February 2012 (undefined)
Primary Completion Date
December 2013 (Anticipated)
Study Completion Date
December 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brasilia University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study aims to investigate the effectiveness of a single application of Er:YAG laser to the nail plate in increasing the efficacy of the amorolfine lacquer used in the treatment of onychomycosis (fungal infection of nails) cause by dermatophyte molds. This clinical trial respective involve 30 subjects with hands or feet distal-lateral subungual onychomycosis (a kind of onychomycosis that does not affect the ungual matrix). The patients will receive treatment for 6 months meanwhile they will be followed up to access efficacy of the treatment by means of the clearance of nail plate infection.
Detailed Description
This is a trial study involving 30 subjects with onychomycosis of hands or feet. The patient must have at least 2 injured nails as each affected nail will receive a different treatment - self-controlled study design.
Therefore, each nail out of two from a single patient will be randomized into the following study arms:
Group A of nails - will receive only weekly application of amorolfine lacquer for a total of 6 months.
Group B of nails - will receive a single application of Er:YAG laser followed by weekly application of amorolfine lacquer for a total of 6 months.
At the end of 6 months the data from both groups, A and B, regarding *clinical cure, *mycological cure and *extent of damage to the nail plates will be analyzed using specific tests.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Onychomycosis
Keywords
Erbium-doped yttrium aluminium garnet laser, Er:YAG, Amorolfine lacquer, Dermatophytes, Subungual distal lateral onychomycosis, Drug delivery
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Er:YAG + amorolfine lacquer
Arm Type
Active Comparator
Arm Description
30 ungual units affected by onychomycosis due to dermatophytes
Arm Title
Amorolfine lacquer
Arm Type
Placebo Comparator
Arm Description
30 ungual units affected by onychomycosis due to dermatophytes
Intervention Type
Device
Intervention Name(s)
Er:YAG laser + amorolfine lacquer
Other Intervention Name(s)
Loceryl, Er:YAG laser
Intervention Description
To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
Intervention Type
Drug
Intervention Name(s)
Amorolfine lacquer
Other Intervention Name(s)
Loceryl
Intervention Description
To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
Primary Outcome Measure Information:
Title
Extent of nail plate damage
Description
At the beginning and after 6 months of treatment both the group, A and B, will have the length from nail cuticle to the closest point of damage to the nail plate measured by a millimeter scale. It will later be accessed to determine the clearance rate of the nail plate achieved with each treatment
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Mycological cure
Description
After 6 months of treatment both the group, A and B, will be accessed by direct mycological examination and culture to evaluate mycological cure
Time Frame
6 months
Title
Clinical cure
Description
After 6 months of treatment both the group, A and B, will be accessed by dermatological examination to evaluate clinical cure
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
19-60 year-old
preserved cognitive status
direct mycological examination or culture showing infection of hands or feet nails by dermatophyte molds
Exclusion Criteria:
diabetes type 1 or 2; peripheral vascular disease
having undergone any treatment in the last 6 months
peripheral nerve disorders (e.g. peripheral neuropathy, Hansen's disease, etc)
willing to paint nail during the study
high blood pressure
use of any immunosuppressive drugs; congenital or acquired immunodeficiency
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Orlando O Morais, Investigator
Phone
+55(61)9916-2339
Email
orlando.unb@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Orlando O Morais, M.D.
Organizational Affiliation
University of Brasilia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital of Brasilia
City
Brasilia
State/Province
Federal District
ZIP/Postal Code
70910-900
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Orlando O Morais, M.D.
Phone
+55(61)99162339
Email
orlando.unb@gmail.com
First Name & Middle Initial & Last Name & Degree
Orlando O Morais, M.D.
12. IPD Sharing Statement
Citations:
PubMed Identifier
24173203
Citation
Morais OO, Costa IM, Gomes CM, Shinzato DH, Ayres GM, Cardoso RM. The use of the Er:YAG 2940nm laser associated with amorolfine lacquer in the treatment of onychomycosis. An Bras Dermatol. 2013 Sep-Oct;88(5):847-9. doi: 10.1590/abd1806-4841.20131932.
Results Reference
derived
Learn more about this trial
Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis
We'll reach out to this number within 24 hrs